Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
06 June 1986Website:
http://www.xoma.comNext earnings report:
08 August 2024Last dividends:
02 April 2024Next dividends:
N/APrice
regular market | Wed, 03 Jul 2024 13:30:00 GMTAnalysts recommendations
Institutional Ownership
XOMA Latest News
XOMA Corporation operates as a biotechnology royalty aggregator, acquiring economic rights to milestones and royalties from approved or clinical-stage drugs. XOMA's diverse IP portfolio spans various therapeutic areas, including oncology, immunology, rare diseases, and acute pain, mitigating investment risks. The recent acquisition of Kinnate Biopharma extends XOMA's portfolio into oncology despite Kinnate selling its crown jewel, exarafenib, before the acquisition.
EMERYVILLE, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share.
XOMA Corporation, a biotech royalty aggregator, revealed today that executives will attend the H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ in New York City on May 20, 2024.
EMERYVILLE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following March 2024 investor conferences:
Xoma (XOMA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
EMERYVILLE, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, announced today Owen Hughes, Executive Chairman, and Brad Sitko, Chief Investment Officer, will be featured in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 2, 2023, at 10:30 AM ET.
What type of business is XOMA?
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
What sector is XOMA in?
XOMA is in the Healthcare sector
What industry is XOMA in?
XOMA is in the Biotechnology industry
What country is XOMA from?
XOMA is headquartered in United States
When did XOMA go public?
XOMA initial public offering (IPO) was on 06 June 1986
What is XOMA website?
https://www.xoma.com
Is XOMA in the S&P 500?
No, XOMA is not included in the S&P 500 index
Is XOMA in the NASDAQ 100?
No, XOMA is not included in the NASDAQ 100 index
Is XOMA in the Dow Jones?
No, XOMA is not included in the Dow Jones index
When does XOMA report earnings?
The next expected earnings date for XOMA is 08 August 2024